ArticleBreast cancer research : BCR2020

Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.

Lori J Goldstein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.